文献速递传染病防控与疫情报告卫生政策与健康促进

直接抗病毒药物时代的丙型肝炎照护级联:一项Meta分析

Hepatitis C Cascade of Care in the Direct-Acting Antivirals Era: A Meta-Analysis.
PubMed 文献 · Am J Prev Med · 2023-06-26

该研究系统检索并Meta分析2014年1月至2021年3月北美、欧洲和澳大利亚的65项研究、共7402185人,评估直接抗病毒药物时代丙型肝炎照护级联各步骤的完成比例。丙型肝炎病毒RNA检测阳性者中29%(95%CI=25%,33%)达到治愈,监狱筛查率43%、急诊科筛查率20%,无家可归者治愈率17%。

要点

  • 丙型肝炎病毒RNA阳性者中62%参加首次照护预约,41%启动治疗,38%完成治疗,29%达到治愈。
  • 监狱或看守所丙型肝炎筛查率为43%,急诊科为20%。
  • 无家可归者照护衔接率为62%,急诊科诊断者为26%;物质使用障碍者治愈率为51%,无家可归者为17%。

核心结论

  • 尽管已有有效的全口服直接抗病毒药物治疗,丙型肝炎照护级联各步骤仍存在持续缺口,尤其在传统上被边缘化的人群中。
  • 针对已识别优先领域(如急诊科)的公共卫生干预可能改善丙型肝炎病毒感染脆弱人群(如物质使用障碍人群)的筛查和医疗留存。

研究设计与样本

  • 系统综述与Meta分析,纳入2014年1月至2021年3月北美、欧洲和澳大利亚报告丙型肝炎照护级联结局(从筛查到治愈)的研究。
  • 共纳入65项研究,合计7402185人。
  • 2022年采用随机效应Meta分析估计合并比例及95%CI。
  • 计算各步骤完成比例时,第1至8步的分子为完成该步的人数;第1至3步的分母为完成前一步的人数,第4至8步的分母为完成第3步的人数。

主要发现

  • 丙型肝炎病毒RNA检测阳性者中,62%(95%CI=55%,70%)参加首次照护预约。
  • 丙型肝炎病毒RNA检测阳性者中,41%(95%CI=37%,45%)启动治疗,38%(95%CI=29%,48%)完成治疗,29%(95%CI=25%,33%)达到治愈。
  • 丙型肝炎筛查率在监狱或看守所为43%(95%CI=22%,66%),在急诊科为20%(95%CI=11%,31%)。
  • 照护衔接率在无家可归者为62%(95%CI=46%,75%),在急诊科诊断者为26%(95%CI=22%,31%)。
  • 治愈率在物质使用障碍者为51%(95%CI=30%,73%),在无家可归者为17%(95%CI=17%,17%);治愈率在美国最低。

临床怎么用

  • 作者认为,针对已识别优先领域(如急诊科)的公共卫生干预可能改善丙型肝炎病毒感染脆弱人群(如物质使用障碍人群)的筛查和医疗留存。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The hepatitis C virus (HCV) epidemic remains a public health problem worldwide. A systematic review and meta-analysis were conducted to provide evidence of outcomes attained across the HCV care cascade in the era of direct-acting antivirals. METHODS: Studies from North America, Europe, and Australia (January 2014 through March 2021) reporting on HCV care cascade outcomes (screening to cure) were included. When calculating the proportions of individuals completing each step, the numerator for Steps 1-8 was the number of individuals completing each step; the denominator was the number of individuals completing the previous step for Steps 1-3 and Step 3 for Steps 4-8. In 2022, random effects meta-analyses were conducted to estimate pooled proportions with 95% CIs. RESULTS: Sixty-five studies comprising 7,402,185 individuals were identified. Among individuals with positive HCV ribonucleic acid test results, 62% (95% CI=55%, 70%) attended their first care appointment, 41% (95% CI=37%, 45%) initiated treatment, 38% (95% CI=29%, 48%) completed treatment, and 29% (95% CI=25%, 33%) achieved cure. HCV screening rates were 43% (95% CI=22%, 66%) in prisons or jails and 20% (95% CI=11%, 31%) in emergency departments. Linkage to care rates were 62% (95% CI=46%, 75%) for homeless individuals and 26% (95% CI=22%, 31%) for individuals diagnosed in emergency departments. Cure rates were 51% (95% CI=30%, 73%) in individuals with substance use disorder and 17% (95% CI=17%, 17%) in homeless individuals. Cure rates were lowest in the U.S. DISCUSSION: Despite the availability of effective all-oral direct-acting antiviral therapies, persistent gaps remain across the HCV care cascade, especially among traditionally marginalized populations. Public health interventions targeting identified priority areas (e.g., emergency departments) may improve screening and healthcare retention of vulnerable populations with HCV infection (e.g., substance use disorder populations).

来源:Am J Prev Med,查看原文。版权归原作者所有。

引用

  1. Hernandez-Con P, Wilson DL, Tang H, et al. Hepatitis C Cascade of Care in the Direct-Acting Antivirals Era: A Meta-Analysis. Am J Prev Med. 2023. PMID: 37380088. doi:10.1016/j.amepre.2023.06.016

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。